Syncom Formulations (India) Limited (SYNCOMF) - Net Assets
Based on the latest financial reports, Syncom Formulations (India) Limited (SYNCOMF) has net assets worth Rs3.78 Billion INR (≈ $40.93 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs4.56 Billion ≈ $49.32 Million USD) and total liabilities (Rs775.88 Million ≈ $8.39 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SYNCOMF asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs3.78 Billion |
| % of Total Assets | 82.99% |
| Annual Growth Rate | 13.82% |
| 5-Year Change | 82.4% |
| 10-Year Change | 214.77% |
| Growth Volatility | 11.38 |
Syncom Formulations (India) Limited - Net Assets Trend (2006–2025)
This chart illustrates how Syncom Formulations (India) Limited's net assets have evolved over time, based on quarterly financial data. Also explore Syncom Formulations (India) Limited asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Syncom Formulations (India) Limited (2006–2025)
The table below shows the annual net assets of Syncom Formulations (India) Limited from 2006 to 2025. For live valuation and market cap data, see SYNCOMF market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs3.42 Billion ≈ $37.00 Million |
+19.09% |
| 2024-03-31 | Rs2.87 Billion ≈ $31.07 Million |
+12.22% |
| 2023-03-31 | Rs2.56 Billion ≈ $27.69 Million |
+15.21% |
| 2022-03-31 | Rs2.22 Billion ≈ $24.03 Million |
+18.47% |
| 2021-03-31 | Rs1.88 Billion ≈ $20.29 Million |
+28.79% |
| 2020-03-31 | Rs1.46 Billion ≈ $15.75 Million |
+9.82% |
| 2019-03-31 | Rs1.33 Billion ≈ $14.34 Million |
+8.76% |
| 2018-03-31 | Rs1.22 Billion ≈ $13.19 Million |
+3.91% |
| 2017-03-31 | Rs1.17 Billion ≈ $12.69 Million |
+7.96% |
| 2016-03-31 | Rs1.09 Billion ≈ $11.76 Million |
+8.46% |
| 2015-03-31 | Rs1.00 Billion ≈ $10.84 Million |
+5.28% |
| 2014-03-31 | Rs951.99 Million ≈ $10.30 Million |
+8.54% |
| 2013-03-31 | Rs877.09 Million ≈ $9.49 Million |
+4.90% |
| 2012-03-31 | Rs836.08 Million ≈ $9.04 Million |
+2.39% |
| 2011-03-31 | Rs816.58 Million ≈ $8.83 Million |
+48.34% |
| 2010-03-31 | Rs550.47 Million ≈ $5.95 Million |
+33.83% |
| 2009-03-31 | Rs411.32 Million ≈ $4.45 Million |
+5.37% |
| 2008-03-31 | Rs390.34 Million ≈ $4.22 Million |
+14.01% |
| 2007-03-31 | Rs342.37 Million ≈ $3.70 Million |
+17.02% |
| 2006-03-31 | Rs292.59 Million ≈ $3.16 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Syncom Formulations (India) Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 154111500000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs1.54 Billion | 45.04% |
| Common Stock | Rs940.00 Million | 27.47% |
| Other Comprehensive Income | Rs696.66 Million | 20.36% |
| Other Components | Rs243.80 Million | 7.13% |
| Total Equity | Rs3.42 Billion | 100.00% |
Syncom Formulations (India) Limited Competitors by Market Cap
The table below lists competitors of Syncom Formulations (India) Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Namyong Terminal PCL
BK:NYT
|
$149.19 Million |
|
Orion Office Reit Inc
NYSE:ONL
|
$149.23 Million |
|
Kotra Industries Bhd
KLSE:0002
|
$149.32 Million |
|
Private Equity Holding AG
SW:PEHN
|
$149.33 Million |
|
Fiamma Holdings Bhd
KLSE:6939
|
$149.12 Million |
|
Paragon Care Limited
F:PXS
|
$149.01 Million |
|
Orogen Royalties Inc
V:OGN
|
$149.00 Million |
|
Apollo Silver Corp
V:APGO
|
$149.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Syncom Formulations (India) Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,881,428,000 to 3,421,576,000, a change of 540,148,000 (18.7%).
- Net income of 494,346,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 45,802,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs494.35 Million | +14.45% |
| Other Comprehensive Income | Rs45.80 Million | +1.34% |
| Total Change | Rs- | 18.75% |
Book Value vs Market Value Analysis
This analysis compares Syncom Formulations (India) Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.72x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 9.55x to 3.72x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-03-31 | Rs1.54 | Rs14.67 | x |
| 2007-03-31 | Rs1.70 | Rs14.67 | x |
| 2008-03-31 | Rs1.88 | Rs14.67 | x |
| 2009-03-31 | Rs1.79 | Rs14.67 | x |
| 2010-03-31 | Rs1.84 | Rs14.67 | x |
| 2011-03-31 | Rs1.05 | Rs14.67 | x |
| 2012-03-31 | Rs1.07 | Rs14.67 | x |
| 2013-03-31 | Rs1.12 | Rs14.67 | x |
| 2014-03-31 | Rs1.70 | Rs14.67 | x |
| 2015-03-31 | Rs1.28 | Rs14.67 | x |
| 2016-03-31 | Rs1.39 | Rs14.67 | x |
| 2017-03-31 | Rs1.43 | Rs14.67 | x |
| 2018-03-31 | Rs1.69 | Rs14.67 | x |
| 2019-03-31 | Rs1.67 | Rs14.67 | x |
| 2020-03-31 | Rs1.87 | Rs14.67 | x |
| 2021-03-31 | Rs2.37 | Rs14.67 | x |
| 2022-03-31 | Rs2.55 | Rs14.67 | x |
| 2023-03-31 | Rs2.76 | Rs14.67 | x |
| 2024-03-31 | Rs3.07 | Rs14.67 | x |
| 2025-03-31 | Rs3.95 | Rs14.67 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Syncom Formulations (India) Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.45%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.63%
- • Asset Turnover: 1.13x
- • Equity Multiplier: 1.21x
- Recent ROE (14.45%) is above the historical average (9.10%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 16.80% | 9.77% | 1.06x | 1.62x | Rs19.88 Million |
| 2007 | 11.91% | 7.07% | 1.07x | 1.58x | Rs6.54 Million |
| 2008 | 9.19% | 5.29% | 1.00x | 1.74x | Rs-3.18 Million |
| 2009 | 6.43% | 4.59% | 0.91x | 1.54x | Rs-14.69 Million |
| 2010 | 8.02% | 5.17% | 0.93x | 1.68x | Rs-10.91 Million |
| 2011 | 0.25% | 0.27% | 0.68x | 1.38x | Rs-79.62 Million |
| 2012 | 4.19% | 2.96% | 1.05x | 1.35x | Rs-48.55 Million |
| 2013 | 6.45% | 4.92% | 0.94x | 1.40x | Rs-31.15 Million |
| 2014 | 9.79% | 6.16% | 1.08x | 1.47x | Rs-2.03 Million |
| 2015 | 9.73% | 5.63% | 1.26x | 1.37x | Rs-2.66 Million |
| 2016 | 9.53% | 5.63% | 1.05x | 1.61x | Rs-5.14 Million |
| 2017 | 8.98% | 5.70% | 1.03x | 1.54x | Rs-12.01 Million |
| 2018 | 7.09% | 5.61% | 0.90x | 1.40x | Rs-35.47 Million |
| 2019 | 8.36% | 6.09% | 1.05x | 1.30x | Rs-21.72 Million |
| 2020 | 9.79% | 7.12% | 1.11x | 1.24x | Rs-3.12 Million |
| 2021 | 15.55% | 12.19% | 0.82x | 1.55x | Rs104.14 Million |
| 2022 | 8.91% | 9.09% | 0.71x | 1.39x | Rs-24.32 Million |
| 2023 | 7.84% | 8.95% | 0.59x | 1.48x | Rs-55.31 Million |
| 2024 | 8.79% | 9.61% | 0.65x | 1.40x | Rs-35.00 Million |
| 2025 | 14.45% | 10.63% | 1.13x | 1.21x | Rs152.19 Million |
Industry Comparison
This section compares Syncom Formulations (India) Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $34,421,734,672
- Average return on equity (ROE) among peers: 16.28%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Syncom Formulations (India) Limited (SYNCOMF) | Rs3.78 Billion | 16.80% | 0.20x | $149.13 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $334.70 Million | 1.97% | 2.20x | $28.25 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $10.36 Billion | 19.79% | 1.13x | $382.88 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $2.31 Million | -8.08% | 0.08x | $751.12 Million |
| Abbott India Limited (ABBOTINDIA) | $2.46 Billion | 24.35% | 0.39x | $6.14 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $1.16 Billion | 12.69% | 1.32x | $4.10 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.23 Billion | 13.11% | 3.52x | $922.41 Million |
| Alkem Laboratories Limited (ALKEM) | $94.35 Billion | 10.43% | 0.46x | $7.22 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $183.78 Million | 32.19% | 1.01x | $171.45 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $8.85 Billion | 31.98% | 0.86x | $1.67 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $219.29 Billion | 24.33% | 0.54x | $9.34 Billion |
About Syncom Formulations (India) Limited
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and su… Read more